A Phase 3 interventional study of Bosentan 62.5 mg and Bosentan 125 mg in Digital Ulcers, sponsored by Actelion. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-04.
Sponsored by Actelion (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The aim of the study is to collect long-term efficacy, tolerability and safety data of bosentan in Systemic Sclerosis (SSc) patients suffering from ischemic digital ulcers (DUs).
29 studies on the registry are indexed under digital ulcers; 7 are open to participants now.
This study's enrollment of 116 is above the median of 40 across 23 interventional studies indexed under digital ulcers.
Browse digital ulcers studies →Actelion is the lead sponsor of 143 studies on the registry; 1 is open to participants now.
Of its 28 completed or terminated interventional studies of FDA-regulated products, 25 (89%) have results posted.
First submitted before Actelion became part of Johnson & Johnson.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bosentan 62.5 mg tablets b.i.d. for the first 4 weeks followed by bosentan 125 mg b.i.d. thereafter
Drug: Bosentan 62.5 mg · Drug: Bosentan 125 mg
Bosentan 62.5-mg oral tablets twice daily (b.i.d.) for 4 weeks (initial dose)
Bosentan 125-mg oral tablets administered b.i.d. (target dose)
Time to Complete Healing of Each Baseline DU
Time frame: Baseline to healing
Time to Complete Healing of Each New DU
Time frame: New DU occurence to healing
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Dressing
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Arising
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Eating
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Walking
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Hygiene
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Reach
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Grip
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score: Activity
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
Time frame: 80 weeks
Mean Changes From Baseline at Each 16 Week Interval up to Week 80 in Overall Hand Pain Related to Finger Ulcers
Overall hand pain related to finger ulcers was assessed by the patient using a Visual Analogue Scale. Patients were instructed to score their pain by marking on the continuous 10-cm scale, where 0 (left) was no pain and 100 (right) very severe pain, in response to the question, "How much pain have you had because of your finger ulcers in the past week?" The investigator measured the distance in millimeters between 0 and the patient mark with the ruler provided and recorded the distance.
Time frame: 80 weeks
Mean Change From Baseline at Each 16 Week Interval up to Week 80 in the UK Systemic Sclerosis Functional Score (UKFS)
UKFS relates to upper and lower extremity function and muscle weakness. For each item, the patient indicated the responses that best described their current ability: "able to perform in a normal manner," "able to perform with alteration in style," "can only manage with difficulty," and "impossible to achieve." Each response was given an integer from 0 (able to perform in a normal manner) to 3 (impossible to achieve), and the sum of individual responses provided an overall score of 0 to 33. Missing values were replaced with the worst value the patient reported on the other items at that visit.
Time frame: 80 weeks
Total Number of New Digital Ulcers (DUs) Per Patient Observed by the Investigator at Planned Visits
The total number of new DUs per patient observed by the investigator at planned visits and new transient DUs recorded in the patient diary (a patient diary was used to record DUs that might appear and disappear between two planned visits) were assessed at each clinic visit
Time frame: At planned visits up to week 80
Adverse Events up to 24 Hours After Last Study Medication
Number of patients with at least one treatment-emergent adverse event. All adverse events that occurred after study drug initiation and up to 24 hours after study drug discontinuation were to be recorded.
Time frame: 80 weeks
Adverse Events Leading to Permanent Discontinuation of the Study Medication
Number of patients with an adverse event leading to permanent discontinuation of the study treatment
Time frame: 80 weeks
Serious Adverse Events up to 28 Days After Last Study Medication
Number of patients with at least one treatment-emergent serious adverse event (TESAE) were reported. TESAEs are serious AEs that occurred after study drug initiation and up to 28 days after study drug discontinuation. More details on the SAEs are provided in the specific Adverse Events Section
Time frame: 80 weeks
Patients were enrolled at 33 centers in 7 countries (Canada, France, Germany, Italy, Switzerland, UK, and USA. The first patient enrolled and started treatment on 8 July 2004 and the last patient enrolled and started treatment on 20 October 2005.
| Milestone | Bosentan |
|---|---|
| Started | 116 |
| Completed | 56 |
| Not completed | 60 |
| Withdrew: Adverse event | 36 |
| Withdrew: Withdrawal of consent | 14 |
| Withdrew: Administrative | 7 |
| Withdrew: Lost to follow-up | 3 |
No measurements were reported for this outcome.
No measurements were reported for this outcome.
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.3 ± 0.6 |
| change from baseline to week 32 | -0.2 ± 0.7 |
| change from baseline to week 48 | -0.1 ± 0.7 |
| change from baseline to week 64 | -0.1 ± 0.7 |
| change from baseline to week 80 | -0.1 ± 0.7 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | 0.0 ± 0.6 |
| change from baseline to week 32 | -0.0 ± 0.6 |
| change from baseline to week 48 | 0.1 ± 0.6 |
| change from baseline to week 64 | 0.1 ± 0.7 |
| change from baseline to week 80 | 0.1 ± 0.6 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.2 ± 0.6 |
| change from baseline to week 32 | -0.1 ± 0.7 |
| change from baseline to week 48 | -0.2 ± 0.7 |
| change from baseline to week 64 | -0.1 ± 0.6 |
| change from baseline to week 80 | -0.1 ± 0.7 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.1 ± 0.6 |
| change from baseline to week 32 | 0.0 ± 0.7 |
| change from baseline to week 48 | 0.1 ± 0.7 |
| change from baseline to week 64 | 0.1 ± 0.8 |
| change from baseline to week 80 | 0.1 ± 0.8 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.0 ± 0.7 |
| change from baseline to week 32 | -0.0 ± 0.8 |
| change from baseline to week 48 | -0.0 ± 0.8 |
| change from baseline to week 64 | 0.1 ± 0.7 |
| change from baseline to week 80 | 0.2 ± 0.8 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.1 ± 0.7 |
| change from baseline to week 32 | 0.0 ± 0.7 |
| change from baseline to week 48 | 0.0 ± 0.8 |
| change from baseline to week 64 | 0.1 ± 0.8 |
| change from baseline to week 80 | 0.0 ± 0.7 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.1 ± 0.7 |
| change from baseline to week 32 | -0.2 ± 0.7 |
| change from baseline to week 48 | -0.1 ± 0.7 |
| change from baseline to week 64 | -0.1 ± 0.7 |
| change from baseline to week 80 | -0.1 ± 0.7 |
SHAQ evaluates physical disability. Patients were instructed to rate their capacity to perform activities of daily living within the previous 7 days by checking one of the following descriptors: "without any difficulty", "with some difficulty," "with much difficulty," or "unable to do," equivalent to scores of 0, 1, 2, and 3, respectively. Items were categorized into 8 domains: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities.
| scores on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -0.2 ± 0.5 |
| change from baseline to week 32 | -0.1 ± 0.7 |
| change from baseline to week 48 | -0.1 ± 0.7 |
| change from baseline to week 64 | -0.1 ± 0.7 |
| change from baseline to week 80 | -0.1 ± 0.6 |
Overall hand pain related to finger ulcers was assessed by the patient using a Visual Analogue Scale. Patients were instructed to score their pain by marking on the continuous 10-cm scale, where 0 (left) was no pain and 100 (right) very severe pain, in response to the question, "How much pain have you had because of your finger ulcers in the past week?" The investigator measured the distance in millimeters between 0 and the patient mark with the ruler provided and recorded the distance.
| mm | Bosentan |
|---|---|
| change from baseline to week 16 | -21.59 ± 28.02 |
| change from baseline to week 32 | -28.16 ± 32.64 |
| change from baseline to week 48 | -21.90 ± 32.09 |
| change from baseline to week 64 | -22.96 ± 33.27 |
| change from baseline to week 80 | -24.29 ± 36.55 |
UKFS relates to upper and lower extremity function and muscle weakness. For each item, the patient indicated the responses that best described their current ability: "able to perform in a normal manner," "able to perform with alteration in style," "can only manage with difficulty," and "impossible to achieve." Each response was given an integer from 0 (able to perform in a normal manner) to 3 (impossible to achieve), and the sum of individual responses provided an overall score of 0 to 33. Missing values were replaced with the worst value the patient reported on the other items at that visit.
| score on a scale | Bosentan |
|---|---|
| change from baseline to week 16 | -1.37 ± 3.64 |
| change from baseline to week 32 | -1.25 ± 4.01 |
| change from baseline to week 48 | -0.89 ± 4.98 |
| change from baseline to week 64 | -1.17 ± 4.00 |
| change from baseline to week 80 | -0.45 ± 4.66 |
The total number of new DUs per patient observed by the investigator at planned visits and new transient DUs recorded in the patient diary (a patient diary was used to record DUs that might appear and disappear between two planned visits) were assessed at each clinic visit
| number of new digital ulcers | 0 New Ulcers | At Least 1 New Ulcer | At Least 2 New Ulcers | At Least 3 New Ulcers | At Least 4 New Ulcers | At Least 5 New Ulcers |
|---|---|---|---|---|---|---|
| Week 0-4 | 85 | 29 | 17 | 6 | 4 | 3 |
| Week 4-8 | 73 | 34 | 15 | 6 | 4 | 3 |
| Week 8-16 | 63 | 40 | 22 | 9 | 7 | 5 |
| Week 16-24 | 64 | 36 | 17 | 11 | 4 | 2 |
| Week 24-32 | 56 | 41 | 22 | 12 | 8 | 4 |
| Week 32-40 | 59 | 35 | 15 | 7 | 5 | 4 |
| Week 40-48 | 52 | 36 | 20 | 11 | 5 | 3 |
| Week 48-56 | 50 | 37 | 18 | 13 | 7 | 5 |
| Week 56-64 | 48 | 38 | 14 | 7 | 4 | 3 |
| Week 64-72 | 51 | 35 | 24 | 15 | 10 | 8 |
| Week 72-80 | 51 | 32 | 18 | 9 | 4 | 2 |
Number of patients with at least one treatment-emergent adverse event. All adverse events that occurred after study drug initiation and up to 24 hours after study drug discontinuation were to be recorded.
| participants | Bosentan |
|---|---|
| Adverse Events up to 24 Hours After Last Study Medication | 111 |
Number of patients with an adverse event leading to permanent discontinuation of the study treatment
| participants | Bosentan |
|---|---|
| Adverse Events Leading to Permanent Discontinuation of the Study Medication | 36 |
Number of patients with at least one treatment-emergent serious adverse event (TESAE) were reported. TESAEs are serious AEs that occurred after study drug initiation and up to 28 days after study drug discontinuation. More details on the SAEs are provided in the specific Adverse Events Section
| Participants | Bosentan |
|---|---|
| Serious Adverse Events up to 28 Days After Last Study Medication | 45 |
Collected over 80 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bosentan | 6/116 (5.2%) | 45/116 (38.8%) | 111/116 (95.7%) |
| Event | Bosentan |
|---|---|
| PNEUMONIAInfections and infestations | 6/116 |
| DYSPNOEARespiratory, thoracic and mediastinal disorders | 6/116 |
| SKIN ULCERSkin and subcutaneous tissue disorders | 5/116 |
| INFECTED SKIN ULCERInfections and infestations | 4/116 |
| PERIPHERAL ISCHAEMIAVascular disorders | 4/116 |
| CELLULITISInfections and infestations | 2/116 |
| DEVICE RELATED INFECTIONInfections and infestations | 2/116 |
| SEPSISInfections and infestations | 2/116 |
| PULMONARY FIBROSISRespiratory, thoracic and mediastinal disorders | 2/116 |
| PULMONARY HYPERTENSIONRespiratory, thoracic and mediastinal disorders | 2/116 |
| Event | Bosentan |
|---|---|
| SKIN ULCERSkin and subcutaneous tissue disorders | 26/116 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 24/116 |
| ARTHRALGIAMusculoskeletal and connective tissue disorders | 22/116 |
| DIARRHOEAGastrointestinal disorders | 21/116 |
| INFECTED SKIN ULCERInfections and infestations | 21/116 |
| LOCALISED INFECTIONInfections and infestations | 17/116 |
| COUGHRespiratory, thoracic and mediastinal disorders | 15/116 |
| HEADACHENervous system disorders | 14/116 |
| RASHSkin and subcutaneous tissue disorders | 14/116 |
| NASOPHARYNGITISInfections and infestations | 13/116 |
| Age, Continuous(years) | Bosentan |
|---|---|
| Mean | 49.3 ± 12.0 |
| Age, Customized(Participants) | Bosentan |
|---|---|
| Between 24 and 79 years | 116 |
| Sex: Female, Male(Participants) | Bosentan |
|---|---|
| Female | 87 |
| Male | 29 |
| Region of Enrollment(Participants) | Bosentan |
|---|---|
| Canada | 11 |
| France | 10 |
| Germany | 9 |
| Italy | 9 |
| Switzerland | 4 |
| United Kingdom | 6 |
| United States | 67 |
| Scleroderma Health Assessment Questionnaire (SHAQ) Individual Domain Score(score on a scale) | Bosentan |
|---|---|
| Dressing | 1.3 ± 0.9 |
| Arising | 0.5 ± 0.8 |
| Eating | 1.5 ± 1.0 |
| Walking | 0.5 ± 0.7 |
| Hygiene | 0.9 ± 1.0 |
| Reach | 1.1 ± 0.9 |
| Grip | 1.1 ± 0.8 |
| Activity | 1.0 ± 0.9 |
| Overall hand pain(mm) | Bosentan |
|---|---|
| Mean | 58.62 ± 29.80 |
| United Kingdom Scleroderma Functional Score (UKFS)(score on a scale) | Bosentan |
|---|---|
| Mean | 11.06 ± 7.50 |
No study locations are listed for this record.
Ran from Jul 2004 to primary completion in Jan 2009, 54 months.
Results were first posted in Aug 2012, 3 years 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Bosentan